Leerink Partners Starts Maze Therapeutics (MAZE) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TD Cowen Starts Maze Therapeutics (MAZE) at Buy
February 25, 2025 5:30 AM ESTTD Cowen analyst Tyler Van Buren initiates coverage on Maze Therapeutics (NASDAQ: MAZE) with a Buy rating.
The analyst comments "MZE829 (oral APOL1 inhibitor) could address the majority of >1M AKD patients and is ~100x more potent than Vertex's inaxaplin. MZE782 (novel oral... More
Guggenheim Starts Maze Therapeutics (MAZE) at Buy
February 25, 2025 12:59 AM ESTGuggenheim analyst Debjit Chattopadhyay initiates coverage on Maze Therapeutics (NASDAQ: MAZE) with a Buy rating and a price target of $19.00.
The analyst comments: "Leveraging the companys Compass platform, mgmt has advanced three small molecules into clinical development. These investigational medicines engage genetic targets... More
JPMorgan Starts Maze Therapeutics (MAZE) at Overweight
February 25, 2025 12:58 AM ESTJPMorgan analyst Anupam Rama initiates coverage on Maze Therapeutics (NASDAQ: MAZE) with a Overweight rating and a price target of $30.00.
The analyst comments: "The companys proprietary COMPASS platform has produced multiple shots on goal to date. Indeed, lead asset MZE829 (APOL1 inhibitor) in APOL1 kidney disease (AKD) is currently in a phase 2 study, with initial or first top-line data from one of the three cohorts... More
